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1088A Retrospective Comparison of Tacrolimus versus
CyclosporinewithMethotrexate for Immunosuppression
after Allogeneic Hematopoietic Cell Transplantation
with Mobilized Blood Cells
Yoshihiro Inamoto,1 Mary E. D. Flowers,1,2 Frederick R. Appelbaum,1,2 Paul A. Carpenter,1,3
H. Joachim Deeg,1,2 Terry Furlong,1,2 Hans-Peter Kiem,1,2 Marco Mielcarek,1,2
Richard A. Nash,1,2 Rainer F. Storb,1,2 Robert P. Witherspoon,1,2
Barry E. Storer,1,4 Paul J. Martin1,2This retrospective study was performed to compare results with tacrolimus versus cyclosporine in combi-
nation with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation (HCT)
with granulocyte colony-stimulating factor–mobilized blood cells. The cohort included 456 consecutive pa-
tients who received first allogeneic T cell-replete HCTwith mobilized blood cells from related or unrelated
donors after high-intensity conditioning for treatment of hematologic malignancies. Study endpoints included
grades II-IV acute graft-versus-host disease (aGVHD), grades III-IV aGVHD, chronic GVHD (cGVHD), end of
treatment for cGVHD, overall mortality, disease-free survival (DFS), recurrent malignancy, and nonrelapse
mortality (NRM). Adjustedmultivariate Cox regression analysis showed no statistically significant differences
between tacrolimus and cyclosporine for any of the endpoints tested. Although the size of the cohort is not
sufficient to exclude clinically meaningful differences in outcomes, these results support the continued use of
cyclosporine at centers that have not adopted tacrolimus as the standard of care after HCTwith mobilized
blood cells after high-intensity conditioning regimens. A larger registry study should be performed to provide
more definitive information comparing outcomes with the 2 calcineurin inhibitors.
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Graft-versus-host disease (GVHD) is a frequent
immunologic complication after allogeneic hemato-
poietic cell transplantation (HCT).Cyclosporine or ta-
crolimus in combination with other agents represent
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domized prospective phase III studies have indicated
that the risk of grades II-IV acuteGVHD(aGVHD) af-
ter bone marrow transplantation with related or unre-
lated donors was lower with the use of tacrolimus than
with cyclosporine, in combination with methotrexate
[1-3]. Overall survival (OS) appeared similar between
the groups [1,3], although an imbalanced distribution
of risk factors confounded the interpretation of
results in 1 of the studies [2,4].
The source of cells used forHCThas changed since
the 1990s,when the trials comparing tacrolimus and cy-
closporine were done. Granulocyte colony-stimulating
factor (G-CSF)–mobilized blood cells are now used
more frequently than bone marrow cells for HCT in
adults with high-intensity conditioning [5,6]. The
different composition of grafts between bone marrow
and mobilized blood cells might influence the relative
efficacy of the 2 calcineurin inhibitors. Outcomes with
the 2 calcineurin inhibitors after HCT with G-CSF–
mobilized blood cells after high-intensity conditioning
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practices, such as the lower targeted concentration of
tacrolimus and the use of ursodeoxycholic acid to pre-
vent hepatic complications, could affect the relative ef-
ficacy of the 2 calcineurin inhibitors.METHODS
Patients
The study cohort included 456 consecutive pa-
tients who received first allogeneic T cell-replete
HCT with G-CSF–mobilized blood cells from related
or unrelated donors after high-intensity conditioning
for treatment of hematologic malignancies between
July 1, 2003, and December 31, 2009, at our center.
High-intensity (ie, ‘‘myeloablative’’) conditioning reg-
imens included fractionated total-body irradiation
(TBI) at $12.0 Gy or busulfan at 4 mg/kg/day or
130 mg/m2/day for 4 consecutive days. Only patients
who received either tacrolimus or cyclosporine in
combination with methotrexate (MTX) for GVHD
prophylaxis were included. Patients who received an-
tithymocyte globulin (ATG) to prevent GVHD were
excluded. Patients signed consent forms allowingmed-
ical records to be used for research, and the institu-
tional review board approved the study.
Posttransplant Management
All patients received ursodeoxycholic acid from 2
weeks before conditioning until 90 days after HCT
to prevent hepatic complications, and all patients re-
ceived immunosuppression with either tacrolimus or
cyclosporine in combination with methotrexate after
HCT. Methotrexate was administered at 15 mg/m2
on day 1 and at 10 mg/m2 on days 3, 6, and 11 after
HCT. Between 2003 and 2005, both tacrolimus and
cyclosporine were used in parallel depending on the
particular protocol. Thereafter, tacrolimus was the
standard adopted for most protocols at our center. Cy-
closporine dosing was adjusted to maintain whole
blood trough concentrations at 150 to 450 ng/mL, as
measured by immunoassay. Tacrolimus dosing was ad-
justed to maintain concentrations at 5 to 15 ng/mL, as
measured by a liquid chromatography-tandem mass
spectrometry assay for the parent compound.
Study Endpoints
Study endpoints included grades II-IV aGVHD,
grades III-IV aGVHD, chronic GVHD (cGVHD),
end of systemic treatment for cGVHD (ie, duration
of treatment for patients with cGVHD), overall mor-
tality, disease-free survival (DFS), recurrent malig-
nancy, and nonrelapse mortality (NRM). Acute
GVHD was graded according to previously described
criteria [7], and cGVHD was diagnosed according to
NIH criteria [8]. Grade II GVHD was subdividedaccording to the extent of liver and skin involvement
[9]. Most patients with grade IIa GVHD had upper
gastrointestinal symptoms, with or without stage 1
or stage 2 skin involvement (ie,\50% body surface
affected by rash) and no liver involvement. Grade IIb
GVHD included patients with stage 3 skin disease
($50% body surface affected by rash) or stage 1 liver
involvement.
Statistical Analysis
Kaplan-Meier estimates were used for OS and
DFS, and cumulative incidence estimates were used
for other endpoints [10]. Multivariate Cox regression
models were used to evaluate hazard ratios for results
of tacrolimus compared with cyclosporine. The
models were adjusted for patient age, donor type, re-
cipient and donor gender combination, disease type,
disease risk category, use of TBI in the conditioning
regimen, and year of HCT. The analysis was per-
formed during July 2010.RESULTS
Patient Characteristics
Themedian age of patients was 47 years (range: 1-66
years).Of the456patients, 232 (51%)hadHLA-identical
related donors, 187 (41%) had HLA-matched unrelated
donors, and 37 (8%) had HLA-mismatched related
or unrelated donors. The distributions of diagnoses at
transplant, HLA-matching and donor type, and year of
transplantation showed statistically significant differ-
ences according to typeof immunosuppression (Table1).
Transplant Outcomes
The median duration of follow-up among survi-
vors was 45 months (range: 3-85 months) after
HCT. Cumulative incidence rates of grades II-IV,
IIb-IV, and III-IV aGVHD at 120 days were 71%,
55%, and 11%, respectively, and the cumulative inci-
dence of cGVHD at 3 years after HCT was 44%. The
cumulative incidence of discontinued systemic treat-
ment for cGVHD at 2 years after the onset of treat-
ment for cGVHD was 16%. The remaining patients
with cGVHD either continued treatment for more
than 2 years or died or had recurrent malignancy dur-
ing continued treatment within 2 years after the onset
of the disease. OS and DFS rates at 3 years after HCT
were 62% and 55%, respectively. The cumulative in-
cidence rates of recurrent malignancy and NRM at 3
years after HCT were 28% and 18%, respectively.
Multivariate Analysis of Outcomes for
Tacrolimus Compared with Cyclosporine
Adjusted multivariate Cox regression analysis
showed no statistically significant differences between
Table 1. Patient Characteristics According to Type of Immunosuppression
Characteristic Tacrolimus (n 5 292) Cyclosporine (n 5 164) P value
Patient age (years), median (range) 47 (1-66) 46 (9-64) .60
Diagnosis at transplant, no. (%) <.0001
Acute myeloid leukemia 125 (43) 59 (36)
Acute lymphoblastic leukemia 51 (17) 21 (13)
Chronic myeloid leukemia 16 (5) 31 (19)
Myelodysplastic syndromes or myeloproliferative neoplasms 86 (29) 40 (24)
Other (CLL, HD, NHL, MM) 14 (5) 13 (8)
Disease risk category at transplant,* no. (%) .31
Low risk 168 (58) 86 (52)
Intermediate risk 14 (5) 13 (8)
High risk 110 (38) 65 (40)
Donor/patient gender, no. (%) .49
Female/male 78 (27) 39 (24)
Other 214 (73) 125 (76)
High intensity conditioning regimens, no. (%) .98
with total-body irradiation ($1200 cGy) 100 (34) 56 (34)
without total-body irradiation 192 (66) 108 (66)
HLA-matching and donor type, no. (%) <.0001
HLA-identical related 147 (50) 85 (52)
HLA-matched unrelated 135 (46) 52 (32)
HLA-mismatched 10 (3) 27 (16)
Year of transplantation, no. (%) <.0001
2003-2004 2 (1) 132 (80)
2005-2006 118 (40) 26 (16)
2007-2009 172 (59) 6 (4)
CLL indicates chronic lymphocytic leukemia; HD, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; HLA, human leukocyte
antigen.
*The low-risk category included chronic myeloid leukemia in chronic phase, acute leukemia in remission, and refractory anemia without excess blasts.
The intermediate-risk category included CLL, HD, NHL, and MM. The high-risk category included all other diseases and stages.
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tested (Table 2). Further analysis did not identify any
subgroup according to age, diagnosis, disease risk, re-
cipient and donor gender combination, conditioning
regimen, or donor type in which the risk of grades
II-IV GVHD was lower with tacrolimus than with cy-
closporine (data not shown).DISCUSSION
Our retrospective results, which demonstrate that
tacrolimus offered no statistically significant advantage
over cyclosporine for preventing grades II-IV aGVHD,
contrast with results from 3 previous randomized pro-Table 2. Multivariate Analysis of Outcomes for Tacrolimus Compa
Endpoint No. of Events
Grades II-IV acute GVHD 325
Grades IIb-IV acute GVHD† 158
Grades III-IV acute GVHD 51
Chronic GVHD 190
End of systemic treatment for chronic GVHD 48
Overall mortality 177
Disease-free survival 211
Recurrent malignancy 125
Nonrelapse mortality 86
CI indicates confidence interval; GVHD, graft-versus-host disease.
*The models were adjusted for patient age, donor type, recipient, and donor g
irradiation in the conditioning regimen, and year of transplantation.
†See Methods for definition of grade IIb GVHD.spective studies, which all demonstrated that the risk
of aGVHD after bone marrow transplantation was
lower with the use of tacrolimus compared with cyclo-
sporine [1-3]. At least 2 explanations might account for
the different results. First, the higher risks of aGVHD
and cGVHD after HCT with G-CSF–mobilized
blood cells compared with bone marrow might
influence the relative efficacy of the 2 calcineurin
inhibitors [11-14]. Second, the targeted whole blood
concentration of tacrolimus used at our center was
lower than the concentrations evaluated in the
prospective trials (10-40, 10-30, and 20-25 ng/mL,
respectively) [1-3], but other studies have suggested
that tacrolimus levels .20 ng/mL increased the risk of
toxicity without decreasing the risk of GVHD [15,16].red with Cyclosporine
Hazard Ratio* (95% CI) P value
1.12 (0.80-1.55) .52
0.81 (0.50-1.33) .41
1.78 (0.75-4.24) .19
0.89 (0.58-1.38) .61
0.83 (0.29-2.42) .73
0.96 (0.62-1.49) .86
1.09 (0.73-1.64) .67
1.36 (0.80-2.30) .25
0.82 (0.43-1.57) .54
ender combination, disease type, disease risk category, use of total-body
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ferences with the 2 calcineurin inhibitors in OS, DFS,
and recurrent malignancy after mobilized blood cell
transplantation are consistent with results from previ-
ous studies of bone marrow transplantation [1,4]. A
randomized, prospective Japanese study showed an
increased incidence of recurrent malignancy with
tacrolimus after bone marrow transplantation from
related donors [3], but this effect was not observed in
a large, retrospective Japanese study [17] or in a ran-
domized, prospective U.S. study [2].
The retrospective Japanese study showed that the
risk of NRM after bone marrow transplantation from
unrelated donors was lower with tacrolimus than with
cyclosporine [17]. In that study, the lower risk of NRM
in the tacrolimus group was associated with a lower
risk of aGVHD and higher survival compared with the
cyclosporine group. The Japanese results differ from
those observed in our retrospective study, suggesting
that the typeof graft or the ethnicityof patientsmight in-
fluence the relative efficacy of calcineurin inhibitors.
The routine use of prophylactic ursodeoxycholic
acid started at our center in 2003 [18,19] and has
decreased the incidence of aGVHD and hepatic
complications (data not shown). The choice of
calcineurin inhibitor was changed to tacrolimus for
virtually all transplant protocols with high-intensity
conditioning at our center in early 2005. Although
we do not believe that any other transplant practices
have changed during the study period, we cannot com-
pletely exclude effects of unknown confounders even if
the multivariate analysis is adjusted for year of trans-
plantation. The incidence of grades II-IV aGVHD at
our center is higher than reported at other centers, re-
flecting a high sensitivity for diagnosing upper gastro-
intestinal GVHD [20]. Even so, we believe that our
results showing no difference in the risk of grades II-
IV aGVHD are likely to be representative of experi-
ence at other centers, because we found no statistically
significant advantage for tacrolimus in preventing
more severe grades IIb-IV or III-IV GVHD.
Our results support the continued use of cyclospor-
ine at centers that have not adopted tacrolimus as the
standard of care after HCT with mobilized blood cells
after high-intensity conditioning regimens, but the size
of our cohort is not sufficient to exclude clinically
meaningful differences in outcomes with the 2 calci-
neurin inhibitors. A larger registry study should be
performed to provide more definitive information
comparing outcomes with the 2 calcineurin inhibitors.ACKNOWLEDGMENTS
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